中国医药上市公司财务绩效评价研究——基于障碍因子诊断分析

A Study on Financial Performance Evaluation of Chinese Pharmaceutical Listed Companies-Based on the Diagnostic Analysis of Obstacle Factors

通过对财务绩效评价相关理论的梳理,选取20家医药上市公司作为研究对象,根据财务体系的4个评价维度,选择14个财务指标构建财务绩效评价体系,使用熵权-TOPSIS模型对研究对象的财务绩效进行综合评价,将障碍因子诊断模型引入其中,最终对医药上市公司财务绩效评价阻碍因素进行分析。结果表明,对于医药上市公司而言,财务绩效水平波动相对明显,排名变动大,影响财务绩效最大的障碍因素主要是总资产运行效率低和应收账款管理水平不高。因此,医药上市公司需要加强资本积累,拓宽投资渠道,提高资产运行效率,加快应收账款的使用效率。

By combing the related theories of financial performance evaluation,20 listed pharmaceutical companies are selected as the research objects;and according to the four evaluation dimensions of the financial system,14 financial indicators are chosen to construct a financial performance evaluation system,and the entropy Weight-TOPSIS model is also used to study and evaluate the financial performance of the research object,and the obstacle factor diagnosis model is introduced into it,and finally the obstacle factors in the financial performance evaluation of listed pharmaceutical companies are analyzed.The results show that for listed pharmaceutical companies,the financial performance level fluctuates significantly and the ranking changes greatly.The main obstacles affecting financial performance are the low efficiency of total asset operation and the low level of accounts receivable management.Therefore,the listed pharmaceutical companies need to strengthen capital accumulation,broaden investment channels,improve asset operation efficiency,and speed up the use efficiency of accounts receivable.